MiettinenMMcCuePASarlomo-RikalaM, et al.GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors. Am J Surg Pathol. 2014;38(1):13-22.
2.
MantillaJGAnticTTretiakovaM. GATA3 As a valuable marker to distinguish clear cell papillary renal cell carcinomas from morphologic mimics. Hum Pathol. 2017;66:152-158.
3.
MochHAminMBBerneyDM, et al.The 2022 World Health Organization classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours. Eur Urol. 2022;82(5):458-468.
4.
WeiS, et al.Papillary renal neoplasm with reverse polarity is often cystic: report of 7 cases and review of 93 cases in the literature. Am J Surg Pathol. 2022;46(3):336-343.
5.
WilliamsonSR. Clear cell papillary renal cell carcinoma: an update after 15 years. Pathology. 2021;53(1):109-119.
6.
WilliamsonSRHesOTrpkovK, et al.Low-grade oncocytic tumour of the kidney is characterised by genetic alterations of TSC1, TSC2, MTOR or PIK3CA and consistent GATA3 positivity. Histopathology. 2023;82(2):296-304.
7.
WhaleyRDChengL. Clinicopathologic and immunohistochemical characterization of sarcomatoid chromophobe renal cell carcinoma: an analysis of 22 cases. Am J Surg Pathol. 2022;46(9):1171-1179.
8.
LiuYDongYGuY, et al.GATA3 aids in distinguishing fumarate hydratase-deficient renal cell carcinoma from papillary renal cell carcinoma. Ann Diagn Pathol. 2022;60:152007.
9.
LauHDChanEFanAC, et al.A clinicopathologic and molecular analysis of fumarate hydratase-deficient renal cell carcinoma in 32 patients. Am J Surg Pathol. 2020;44(1):98-110.
10.
LauryARPeretsRPiaoH, et al.A comprehensive analysis of PAX8 expression in human epithelial tumors. Am J Surg Pathol. 2011;35(6):816-826.
